Showing 3421-3430 of 5689 results for "".
- New Melanoma Treatments Do Not Supplant Surgery as First-Line Therapyhttps://modernod.com/news/new-melanoma-treatments-do-not-supplant-surgery-as-first-line-therapy/2479670/Although several new melanoma treatments have shown promise, none replaces surgery as the primary therapy yet, according to updated guidelines from the American Academy of Dermatology (AAD), as reported in Reuters Health. “Su
- AsclepiX Therapeutics Raises $5 Million to Advance Therapies in AMD and DMEhttps://modernod.com/news/asclepix-therapeutics-raises-5-million-to-advance-therapies-in-amd-and-dme/2479676/AsclepiX Therapeutics announced that it has raised $5 million in convertible note funding to accelerate development of AXT107, its treatment for two leading causes of adult blindness: diabetic macular edema (DME) and wet age-related macular degeneration (AMD). These diseases are now treated with
- NORA and Concussion Legacy Foundation Offer New Educational Resource on Vision Problems and Symptoms Following a Concussionhttps://modernod.com/news/nora-and-concussion-legacy-foundation-offer-new-educational-resource-on-vision-problems-and-symptoms-following-a-concussion/2479702/Following a concussion or other traumatic brain injury (TBI) there is often an interruption in communication between the eyes and the brain. Studies show that at least 50 percent of TBI patients suffer from visual dysfunctions, with one such study finding a 90 percent incidence of post-trauma vis
- Johnson & Johnson Vision to Showcase New Data and Interactive Experiences at 2018 AAOpthttps://modernod.com/news/johnson-johnson-vision-to-showcase-new-data-and-interactive-experiences-at-2018-aaopt/2479707/Johnson & Johnson Vision will highlight new data at the 2018 American Academy of Optometry Annual Meeting (Academy 2018), held November 7-10 in San Antonio, Texas. Two paper presentations highlighting visual performance of photochromic contact lenses were designated among the “Most Newsworthy
- Oyster Point Announces Positive Results From Two Phase 2b Clinical Trials of Investigational Treatments for Dry Eye Diseasehttps://modernod.com/news/oyster-point-announces-positive-results-from-two-phase-2b-clinical-trials-of-investigational-treatments-for-dry-eye-disease/2479733/Oyster Point Pharma announced results from the ONSET and RAINIER studies, two separate phase 2b clinical trials evaluating the company’s novel therapies for the treatment of dry eye disease (DED). Both studies, presented at the Ophthalmology Innovation Summit (OIS) meeting in Chicago, demonstrate
- First Patient Screened in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel for Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitishttps://modernod.com/news/first-patient-screened-in-mallinckrodt-phase-4-trial-of-h-p-acthar-gel-for-severe-noninfectious-intermediate-uveitis-posterior-uveitis-or-panuveitis/2479736/Mallinckrodt confirmed screening of the first patient in the company’s phase 4, multicenter, multiple-dose, open label study to assess the effects of H.P. Acthar Gel as
- Melt Pharmaceuticals Initiates Clinical Development Program for its Patented MK Melt Conscious Sedation Drug Candidatehttps://modernod.com/news/melt-pharmaceuticals-initiates-clinical-development-program-for-its-patented-mk-melt-conscious-sedation-drug-candidate/2479764/Melt Pharmaceuticals, a subsidiary of Imprimis Pharmaceuticals, announced that following the presentation of clinical data on the MKO Melt (midazolam/ketamine/ondansetron) from a 611-patient IRB approved prospective, controlled, randomized, three arm comparator study at the American Academy of Op
- Increasing Surgery Volume Will Fuel Single-Use Ophthalmic Surgical Device Markethttps://modernod.com/news/increasing-surgery-volume-will-fuel-single-use-ophthalmic-surgical-device-market/2479784/According to Market Scope research, two factors will drive healthy growth in the single-use ophthalmic surgical product market over the next 5 years: an aging world population, which will lead to steady growth in ophthalmic surgeries, and rising concerns over cross-contamination. Market Sc
- Konan Medical USA Acquires objectiveFIELD Objective Perimeterhttps://modernod.com/news/konan-medical-usa-acquires-objectivefield-objective-perimeter/2479795/Konan Medical USA has acquired objectiveFIELD, an FDA-cleared device designed to assess the human visual field in an objective and non-contact manner. The device was acquired from the Australian National University (ANU), includes novel features licensed from Seeing Machine
- Optovue Showcases First OCT Angiography Metrics and Non-Contact Method for Corneal Measurements at Vision Expo Westhttps://modernod.com/news/optovue-showcases-worlds-first-oct-angiography-metrics-and-non-contact-method-for-corneal-measurements-at-vision-expo-west/2479832/Optovue showcased its AngioAnalytics platform, the world’s first OCT angiography (OCTA) blood vessel measurement technology to help clinicians manage diseases that cause progressive blindness, and 3D PAR, its 3-dimensional projection artifact removal software at Vision Expo West 2018. The